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1047-185 Postprandial Lipoproteinemia Exhibits a Bimodal 
Response in Metabolic Syndrome Patients
Robert S. Rosenson, Anna Huskin, Northwestern University, Chicago, IL
Background: Metabolic syndrome is defined by abnormal fasting lipids; however post-
prandial lipemia may provide important insights regarding cardiovascular risk in these
subjects. This study evaluated postprandial lipoprotein responses in metabolic syndrome
subjects.
Methods: 43 subjects (31 M, 12 F) with fasting triglycerides > 150 mg/dL and > 2 other
NCEP criteria for the metabolic syndrome received a NCEP Step 2 diet for 6 months. A
standardized oral fat load (50 g/m2) was given. Plasma samples were collected at base-
line, 3 hours, and 8 hours after the last meal. NMR lipoprofiles were analyzed from refrig-
erated plasma. Data are reported as medians.
Results: 28 subjects had an early TG peak and 16 subjects had a late peak. The lipopro-
tein concentrations are described in the table. Late peakers were significantly older (56.9
± 7.6 vs 50.2 ± 10.3, p = 0.03), had higher fasting glucose levels (88.4 ± 12.5 vs 78.1 ±
16.5, p = 0.04), and tended to have more metabolic syndrome risk factors (p = 0.18).
Clearance of chylomicrons and large VLDL were delayed in late vs early peakers (p <
0.01 for each variable) (Table). Small LDL levels fell less rapidly in late peakers than early
peakers (p = 0.02).
Conclusion: Hypertriglyceridemic subjects with the metabolic syndrome exhibit variable
postprandial lipoprotein responses. Delayed lipoprotein clearance is associated with
older age, higher fasting glucose levels, and more metabolic syndrome risk factors. 
1047-186 Raloxifene Improves Lipoprotein, Apolipoprotein and 
Fibrinogen in Postmenopausal Osteoporotic Women 
With or Without Hypertriglyceridemia
Thomas Dayspring, Yongming Qu, Cheryl A. Keech, North Jersey Institute of 
Menopausal Lipidology, Wayne, NJ, Lilly Research Laboratories, Indianapolis, IN
Background: Raloxifene (RLX) is used for prevention and treatment of postmenopausal
osteoporosis and has positive effects on markers of cardiovascular disease, including
lipid lowering. Women with high triglycerides (hTG) are at increased risk of cardiovascu-
lar events.
Methods: We determined the effect of 3 yrs of RLX (60 or 120 mg/d) vs. placebo (PLC)
on lipoproteins, apolipoproteins and fibrinogen in women who were classified as having
hTG (>150 mg/dL) vs. normal TG (nTG, <150mg/dL) at baseline in the Multiple Out-
comes of Raloxifene Evaluation trial. A mixed model repeated measure analysis was
used.
Results: Effect of RLX compared to PLC did not depend on baseline TG status (interac-
tion P>0.1). At baseline, TG levels in hTG (n=446) vs. nTG (n=2213) groups were 204 vs.
91 mg/dL, respectively; hTG women had elevated LDL-C, non-HDL-C, total cholesterol
and low HDL-C (P<.005 vs. nTG). At 3 yrs, RLX improved LDL-C, Apo B, non-HDL-C,
Apo A1, total choelsterol and fibrinogen compared to PLC (both TG groups). RLX was
neutral on HDL-C, but increased Apo A1 compared to PLC in both TG groups. Lipopro-
tein changes occurred at the earliest time point measured (6 mo).
Conclusion: RLX was equally efficacious for nTG and hTG women in improving lipopro-
teins, apolipoproteins and fibrinogen levels.
Table 1. Mean Values (% From Baseline) for Lipoproteins and Fibrinogen at 3 Years 
*P<.01 vs. baseline, for all groups indicated
†RLX vs. PLC within TG group, P<.03
All levels expressed as mg/dL except for fibrinogen (g/L)
1047-187 Cholesterol Goal Attainment Is Associated With Lower 
Incidence of Cardiovascular Events and Cost of Care
Linus Jönsson, Fredrik Borgström, Jan Stålhammar, Evo Alemao, Donald Dongping Yin, 
Karolinska Institutet, Stockholm, Sweden
Introduction: Lowering elevated cholesterol decreases cardiovascular (CV) morbidity
and mortality. However, a majority of treated patients do not reach recommended thera-
peutic goal (LDL < 3 mmol/l and total cholesterol < 5 mmol/l according to European
guidelines). This study describes patterns of lipid-lowering therapy in Swedish primary
care and estimates rate and determinants of goal attainment and its effect on CV events
and costs of care.
Materials and Methods: Total of 9789 patients receiving lipid-lowering treatment
between 1993 and 2003 were included from 29 primary care centers in a defined geo-
graphic area. Data were gathered on health care visits, hospitalizations, lab tests, phar-
maceuticals, co-morbidity and risk factors though retrospective review of computerized
medical records and inpatient and mortality registers. Regression methods were used to
control for baseline differences and estimate event incidences and costs of care.
Results: Within first year of treatment, 4.9% patients were titrated to a higher dose, 2.9%
received an add-on drug, 0.9% had a decrease in dosage and 15.3% discontinued treat-
ment. Average reduction in LDL was 31.1% for patients treated with statin. Overall 28.5%
evaluable patients attained the lipid goals within 3 months, 29.7% within one year. Goal
attainment was significantly higher in patients with low baseline cholesterol level (OR =
0.53), older age (OR = 1.01), prior CV events (OR = 1.53), and who received dose titra-
tion or add-on treatment (OR = 2.27). Incidence of MI, stroke and revascularization pro-
cedures was 16.8, 13.4 and 8.9 per 1000 patients per year. Total annual incidence of CV
events was 155.0 and 18.2 per 1000 patients with and without prior CV events, respec-
tively. Patients who attained lipid goals had 31.4% lower incidence of subsequent events
and lower total discounted costs compared to those not attaining lipid goals (p<0.05) dur-
ing period of observation, controlling for age, gender, previous CHD and diabetes.
Conclusions: A majority (70%) of patients on current lipid management strategy do not
attain lipid goals. However, goal attainment is associated with superior outcome in terms
of reducing CV event rates and health care costs.
1047-188 The Ratio of Oxidized Low-Density to High-Density 
Lipoproteins Is an Independent Predictor of Acute 
Myocardial Infarction in Unstable Coronary Artery 
Disease
Nina Johnston, Tomas Jernberg, Bo Lagerqvist, Agneta Siegbahn, Lars Wallentin, 
University Hospital, Uppsala, Sweden
Background: Early risk stratification is essential in patients with unstable coronary artery
disease (UCAD), i.e. unstable angina or non ST-elevation myocardial infarction (MI). Oxi-
dized low-density lipoprotein (OxLDL) is involved in numerous pathophysiological mecha-
nisms in the development of the disease .The aim of this study was to examine the
prognostic value of OxLDL in this population.
Methods: OxLDL was analyzed in 432 patients with unstable angina or non ST-elevation
MI included in the FRISC II trial. End points were death and myocardial infarction after 2
years.
Results: The median level of OxLDL was 76 (25:th-75:th percentile: 63-88 U/l). The rate
of death and myocardial infarction in relation to OxLDL and the ratio of OxLDL to high-
density lipoprotein (HDL) is shown in the table below . When adjusted for known predic-
tors of adverse outcome, including age, gender, diabetes, prior myocardial infarction, ST-
segment depression, troponin T and treatment strategy (non-invasive/ invasive), the ratio
of OxLDL to HDL was independently associated to the risk of future MI, odds-ratio
(95%CI): 2.23 (1.20-4.15).
CHOL
(mmol/L)
LDL
(mmol/L)
HDL
(mmol/L)
TG
(mmol/L)
Smoking
(%)
Weight
(kg)
Baseline 5.46 3.41 1.08 2.18 34.5 83.1
End of CREP 4.16 2.30 1.12 1.64 10.6 82.0
Follow-up 4.40 2.50 1.14 1.69 12.7 83.3
Variable Early 
Peakers (3 
hours)
Late 
Peakers (8 
hours)
% 
Change
0 to 3 
hours
% 
Change
0 to 8 
hours
% 
Chan
ge
3 to 8 
hours
% 
Chan
ge
0 to 3 
hours
% Change
0 to 8 hours
% 
Chan
ge
3 to 8 
hours
p-value for 
% change
0 to 3 
hours
p-value for 
% change
0 to 8 
hours
p-value for 
% change
3 to 8 
hours
TG 55.1 11.9 -28.8 42.0 52.9 6.7 0.04 <0.01 <0.01
LDL-C 7.0 5.1 -0.6 5.5 9.1 -0.4 0.75 0.85 0.48
HDL-C -8.9 3.9 14.2 -3.1 2.1 1.6 0.10 0.49 0.05
Chylomi
crons
1342.1 151.1 -83.8 609.5 590.9 -8.8 0.27 0.04 <0.01
Large 
VLDL
128.8 42.8 -33.1 56.7 131.1 36.9 0.05 0.04 <0.01
Large 
HDL
-6.0 -6.4 3.8 -9.0 -22.2 -17.5 0.99 0.26 0.03
Small 
LDL
-9.2 -54.6 -48.2 -6.7 -9.5 -6.1 0.94 0.17 0.02
High Triglyceride Normal Triglyceride
Placebo Raloxifene (pooled) Placebo Raloxifene (pooled)
LDL-C* 158
(-2.3)
136†
(-16.5)
151
(-0.6)
135†
(-12.7)
APO B* 158
(-7.5)
145†
(-15.8)
138
(-2.9)
128†
(-11.3)
Non-HDL-C* 195
(-3.9)
173†
(-14.7)
169
(-0.6)
154†
(-10.5)
HDL-C* 49
(5.0)
51
(8.1)
65
(6.3)
65
(6.0)
APO A1 144
(1.9)
151*†
(4.3)
155
(0.2)
159†
(2.2)
Total-C 244*
(-2.5)
225*†
(-10.3)
234
(0.9)
219*†
(-6.4)
Fibrinogen 3.4
(2.9)
2.9*†
(-12.1)
3.3
(6.7)
2.9*†
(-8.9)
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Conclusions: The ratio of OxLDL to HDL seems to be an important predictor of subse-
quent MI in patients with UCAD.
POSTER SESSION
1064 
Pathogenesis and Treatment of the 
Atherosclerotic Plaque
Monday, March 08, 2004, 9:00 a.m.-11:00 a.m.
Morial Convention Center, Hall G
Presentation Hour: 9:00 a.m.-10:00 a.m.
1064-178 A Novel Oral Neutrophil Elastase Inhibitor, ONO-6818, 
Suppressed Early Atherosclerotic Plaque Formation in 
Apolipoprotein E-Knockout Mice
Yoshitaka Iso, Hiroshi Suzuki, Teruko Soda, Fumitaka Tsunoda, Takatoshi Sato, Makoto 
Shoji, Shinji Koba, Eiichi Geshi, Takashi Katagoro, Showa University School of Medicine, 
Tokyo, Japan
Objective: Proteolysis and elastolysis contribute to the development of atherosclerosis.
Neutrophil elastase (NE) can degrade not only elastin but also collagens, fibronectin, and
proteoglycans, and it is predominantly present in neutrophils. However, recent studies
indicated the expression of NE in atheroma-related cells. Therefore, we hypothesized NE
inhibition prevented atherogenesis, and examined whether ONO-6818, an orally active
inhibitor of NE, limited atherosclerotic lesion in apolipoprotein E-knockout mice (ApoE-
KO mice). Methods and Results: ApoE-KO mice (8 weeks of age) were fed a normal
chow diet, and euthanized at the age of 12 weeks. They were divided into 2 groups; (1)
control group (n=8, oral administration of saline) (2) treatment group (n=8, oral adminis-
tration of 100mg/kg ONO-6818 for 4weeks). Plasma cholesterol levels were not signifi-
cantly different between the two groups at the age of 12 weeks. Histological analysis of
atherosclerotic lesions in the aortic root was performed using oil red O stained-sections.
Plaque area was significantly reduced in ApoE-KO mice treated with ONO-6818 com-
pared to the control group (9377 +/- 2078 µm2 versus 28464 +/- 7613 µm2, p=0.02). In
immunohistochemical study, the percent area of macrophage accumulation to the total
cross-sectional vessel wall area was smaller in ApoE-KO mice treated with ONO-6818
than the control group (1.0 +/- 0.2% versus 2.8 +/- 0.9%, p=0.07). The abdominal aortas
of ApoE-KO mice were used for RT-PCR analysis of eNOS mRNA. ONO-6818 prevented
downregulation of eNOS mRNA expression in ApoE-KO mice compared to the controls.
Conclusions: NE inhibitor suppressed early atherosclerotic plaque formation and pro-
tected endothelial function in ApoE-KO mice. These results suggested that NE could be a
new therapeutic target for atherogenesis.
1064-179 Mice Deficient in Leptin or the Leptin Receptor Exhibit 
Reduced Neointima Formation Following Vascular 
Injury
Yuechun Shen, Peter F. Bodary, Daniel T. Eitzman, University of Michigan, Ann Arbor, MI
Background: Elevated levels of plasma leptin have been identified as an independent
risk factor for cardiovascular disease, although the mechanism by which leptin increases
this risk is unknown. We hypothesize that leptin may contribute to vascular disease
through effects on vascular remodeling.
Methods and results: A mouse model of femoral arterial wire injury was used that
induces endothelial damage followed by intimal hyperplasia. We induced arterial injury in
wild type (Lep+/+) (n=8), leptin deficient (Lep-/-) (n=13) and leptin receptor deficient
(LepR-/-) (n=9) mice. Four weeks after injury, the intima/media ratios (I/Ms) of Lep-/- and
LepR-/- mice were 0.80±0.14 and 0.55±0.20, which were significantly reduced compared
to Lep+/+ mice (1.50±0.22) (p<0.01 and <0.02, respectively). To further establish that
leptin was responsible for the altered neointima formation, leptin was replaced in Lep-/-
mice by daily peritoneal injection beginning one day prior to injury until sacrifice. The I/Ms
of Lep-/- mice (n=8) receiving leptin treatment were significantly higher (1.44±0.18) than
Lep-/- mice described in the original cohort (p<0.02). Mice were also treated with an ade-
novirus, expressing murine leptin on the RSV promoter, one day following injury. The I/Ms
of Lep-/- mice (n=6) receiving ad-leptin were 2.04±0.27, which were significantly higher
compared to the I/Ms of the control Lep-/- mice (p<0.004). The I/Ms of LepR-/- mice (n=4)
receiving ad-leptin were 0.50±0.19, which were not different from the I/Ms in the original
group of LepR-/- mice.
Conclusion: These observations demonstrate that mice lacking leptin or the leptin
receptor are protected from neointima formation following vascular injury and suggest
that leptin may play a role in atherosclerosis by promoting lesion growth.
1064-180 Splenectomy and Adoptive Transfer of Splenocytes 
Reveal a Critical Role for Spleen in Mediating Athero-
Protective Effects of Immunization With Apolipoprotein 
B-100-Related Peptide Sequence in Apo E (-/-) Mice
Kuang-Yuh Chyu, Stephanie M. Babbidge, Paul C. Dimayuga, Juliana Yano, Jan Nilsson, 
Bojan Cercek, Prediman K. Shah, Gunilla Nordin Fredrikson, Cedars-Sinai Medical 
Center, Los Angeles, CA, Lund University, Malmo, Sweden
Background: We have previously reported athero-protective effects of immunizing
hypercholesterolemic apo E (-/-) mice with single or mixture of human apo B 100 related
peptides. One such peptide is peptide 2 (ATRFKHLRKYTYNYEAESSS, 95% homology
with murine apo B 100). In this study, we sought to determine the role of spleen in medi-
ating athero-protective effects of peptide 2 immunization.
Methods and Results: Male apo E (-/-) mice were immunized with 33 mcg of peptide 2
at 6 weeks of age and boosted at 9 weeks with Alum as adjuvant. Control group received
Alum only. At 12 weeks splenocytes were harvested, pooled and injected into non-immu-
nized apo E (-/-) mice via tail vein. Both donor and recipient groups were fed high choles-
terol diet until sacrifice at 25 weeks. Splenectomy abolished athero-protective effect of
peptide 2 immunization; whereas adoptive transfer of splenocytes from peptide 2 immu-
nized mice reduced atherosclerosis and cholesterol levels in recipient unimmunized
mice. (Table)
Conclusion: Our data provide proof of principle that spleen plays an important role in
mediating the atheroprotective effects of immunization with a single apo B 100 related
peptide in apo E (-/-) mice. 
When compared to Alum recipient group “*” p < 0.05 and “#” p=0.07 by t-test
1064-181 Distinct Signaling Pathways Mediate Protease Activated 
Receptor-Dependent Endothelial Exocytosis
John H. Cleator, Douglas E. Vaughan, Heidi E. Hamm, Vanderbilt University, Nashville, 
TN
Thrombin stimulation of the release von Willebrand Factor (vWF) and P-selectin from
endothelial cells results in propagation of thrombotic events (vWF- mediated platelet
adhesion and aggregation) and adhesion of neutrophils through P-selectin.The purpose
of this study is to determine which Protease Activated Receptors are responsible for
mediating thrombin-induced release of vWF and P-selectin from human umbilical vein
endothelial cells (HUVEC). HUVEC were stimulated with thrombin, specific PAR-activat-
ing peptides (PAR-AP) or histamine and released vWF was measured in the media
(ELISA), while P-selectin was measured on the cell membranes using a cell-based
ELISA. PAR1-AP and PAR2-AP stimulation of vWF release was less effective when com-
pared to either thrombin or histamine stimulation. However, PAR1-AP stimulation of P-
selectin was as efficacious as histamine or thrombin stimulation. In contrast, PAR2-AP
was significantly less efficacious in stimulating the release of P-selectin than vWF. PAR2-
AP stimulation of mobilization of intracellular Ca2+ was nearly identical to PAR1-AP or
thrombin stimulation of mobilization of intracellular Ca2+. Calcium chelation with BAPTA
nearly completely inhibited thrombin-mediated release of vWF while only inhibiting 50-
60% of thrombin-mediated cell surface expression of P-selectin, suggesting an additional
Ca2+-independent pathway involved in release of P-selectin. Furthermore, pertussis toxin
inhibited the release of vWF, while not effecting P-selectin release, implicating Gi/o in
mediating the release of vWF, but not P-selectin. Immunostaining of P-selectin and vWF
demonstrated co-localization of the two proteins in characteristic Weibel-Palade bodies.
Differential signaling and co-localization of P-selectin with vWF suggest PARs stimulate
the differential release of distinct fractions of Weibel-Palade bodies. Selective pharmaco-
logical targeting of specific PARs and G proteins provides a novel therapeutic strategy for
altering the hemostatic and inflammatory balance of specific vascular beds.
1064-182 Gene Transfer of an ApoA-I Mimetic Peptide Reduces 
Atherosclerosis in Mice
Peter F. Bodary, Yuechun Shen, Randal J. Westrick, Narendra D. Lalwani, Sandra L. 
Drake, Jean-Louis H. Dasseux, Daniel T. Eitzman, University of Michigan, Ann Arbor, MI, 
Esperion Therapeutics, Inc., Ann Arbor, MI
Background. Apolipoprotein A-I (ApoA-I) has been shown to be protective against vas-
cular disease in animal models. The development of peptide-based mimetics of ApoA-1
may provide a particularly useful therapy for patients with atherosclerotic vascular dis-
ease. The goal of this study was to assess the effect of a novel ApoA-I peptide analogue
(ESP 24218, Esperion Therapeutics) designed to activate LCAT and promote reverse
lipid transport (RLT).
Methods and results. Nine week old male mice deficient in the LDL receptor were
begun on a western chow diet to accelerate atherogenesis. At 14 weeks of age, mice
were injected intravenously with saline (n=9) or a recombinant adenovirus expressing
either wild-type ApoA-I (n=9), a 22 amino acid ApoA-I peptide analogue, ESP 24218,
(n=10) or a 22 amino acid control peptide (n=10). At 18 weeks of age, mice were sacri-
ficed and the atherosclerotic surface area was quantified in the aortic arch. The amount
of atherosclerosis was significantly lower in mice expressing either wild-type ApoA-I
Death MI
OxLDL <median (n=206) 8 (4%) 19 (9%)
>median (n=226) 9 (4%) Ns 38 (17%) P=0.02
OxLDL/HDL <median (n=208) 9 (4%) 18 (9%)
>median (n=208) 6 (3%) Ns 37 (18%) P=0.006
LDL <median (n=189) 5 (3%) 26 (14%)
>median (n=197) 9 (5%) Ns 25 (13%) Ns
Cholesterol
(mg/dl)
Aortic plaque
(% area)
Aortic sinus 
plaque size 
(mm sq)
MOMA 
immunoreactivity 
(% plaque)
Alum donor, n=4 1285±114 5.6±5.3 0.55±0.05 4.3±4.6
P2 donor, n=9 910±459 3.0±1.7 0.45±0.18 4.2±3.5
Alum recipient, n=10 941±328 5.1±3.0 0.46±0.15 4.8±3.0
P2 recipient, n=9 560±239* 2.1±1.8* 0.33±0.13# 4.7±5.1
